Johnson & Johnson Stock News

WASHINGTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- The Global Surgical Robotics and Navigation Market size is expected to reach over USD 4.5 Billion by 2028, exhibiting a Compound Annual Growth Rate (CAGR) of 6.1% during the forecast period from 2022 till 2028. The market accounted for a revenue of USD 2.1 Billion in 2021. Market Synopsis In the healthcare sector, increase in automation, high minimally invasive treatments demand, and advanced technology adoption in both developing and developed economies are likely to fuel the market growth for Surgical Robotics and Navigation. The key reason for insubordination of surgical procedures is pain related to invasive procedures. To acquire the key user acceptance players in the market for Surgical Robotics and Navigation are focused more in developing portable and non-invasive robotic platforms, states Vantage Market Research, in a report, titled "Surgical Robotics and Navigation Market by Type (Neurosurgery navigation, Spinal surgical navigation, ENT surgical navigation, Orthopedic surgical navigation), by End User (Hospitals, Ambulatory surgical centers), by Region (North America, Latin America, Europe, Asia Pacific) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

"COVID Exhaustion": People Are "Done Being Told What To Do": Former CBOE Floor Trader Submitted by QTR''s Fringe Finance This is part 2 of an exclusive Fringe Finance interview with former floor trader Ryan Sellers (@OpenOutcrier), where we discuss options trading, trading vs. investing, his outlook on the markets, how the nation and the Fed will navigate 2022 and the state of overall liquidity. Ryan began trading in 2002 on the floor of the Chicago Board of Options Exchange (CBOE) as a market maker in the DJX and SPX pits. In 2005, he joined the proprietary trading firm Trebuchet Financial, where he continued to trade options and equities. In 2014, he began using the @OpenOutcrier Twitter handle to post real-time stock and options trading headlines, breaking news, rumors and strategy. In early 2017, http://openoutcrier.com/ was launched as an extension of the Twitter handle and integrated news platform. The site consists of the OOC Feed, a custom BenzingaPro newswire, chat room, curated social media feed, and searchable archive.

As a trial continues this week on whether Johnson & Johnson (JNJ) can use bankruptcy to handle talc claims against it, at least one lawmaker is attacking the drugmaker''s plan.

New York, USA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Orthobiologics Market is Anticipated to Grow at a CAGR of 4.44% During the Forecast Period (2021-26) | DelveInsight As per DelveInsight analysis, a growing geriatric population at risk of developing various bone degenerative disorders, an increase in traumatic injuries such as car accidents, sports injuries, and others are expected to boost the Orthobiologics market growth. Furthermore rising investments in R&D and collaborations by key manufacturers, as well as an increase in various orthobiologic product approvals will also drive the market. DelveInsight''s Orthobiologics Market Insights and Forecast report provides the current and forecast Orthobiologics market, upcoming developments in the medical devices, individual market shares, challenges, drivers, barriers, market growth trends, and key players in the Orthobiologics market. Some of the Key Highlights from the Orthobiologics Market Report According to DelveInsight analysis, North America is expected to dominate the overall Orthobiologics Market during the forecasted period.

Johnson & Johnson was close to settling most litigation over its talc-based products last year in a deal that would have cost between $4 billion and $5 billion, a company lawyer testified Tuesday, double the amount J&J later offered to resolve the liability through a subsidiary’s bankruptcy.

NEW BRUNSWICK, N.J. , Feb. 15, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today that Darius Adamczyk , Chairman and Chief Executive Officer of Honeywell, has been appointed to its Board of Directors. "I am delighted to welcome Darius to Johnson & Johnson''s Board of Directors," said Alex Gorsky , Executive Chairman, Johnson & Johnson. "Darius is an accomplished global leader with decades of experience and a track record of growing businesses. He is also a champion of sustainability and investments in innovation to improve the lives of people around the world. Darius''s extensive knowledge of numerous business sectors will add important dimension and a unique perspective to the Johnson & Johnson Board of Directors. I am incredibly proud of the background, diversity and caliber of all our Board members and on behalf of the Board, we look forward to working with Darius as the Company continues to deliver transformational innovation, create healthier communities, and put better health within reach of more people around the world." About Darius Adamczyk Darius Adamczyk is a visionary who brings decades of global business leadership …

AC Immune SA (NASDAQ: ACIU ) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ ), have found that an early-stage Alzheimer''s vaccine spurs induction of antibodies that attack a type of tau, a protein in the brain that contributes to the disease. The interim data for ACI-35.030 come from the high-dose group … Full story available on Benzinga.com

Adding AstraZeneca Plc''s (NASDAQ: AZN ) Lynparza to Johnson & Johnson''s (NYSE: JNJ ) Zytiga (abiraterone) extended the time to live without disease progression in patients with newly diagnosed metastatic, castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair (HRR) gene mutations. The Lynparza combination pared down that risk by 34% over Zytiga alone, according to phase 3 data released at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The Lynparza combo added … Full story available on Benzinga.com

(Bloomberg) -- Johnson & Johnson adopted its controversial strategy for battling cancer claims tied to baby powder after a $2 billion court loss sparked concern that the company’s perfect credit rating could be damaged by the growing number of similar lawsuits, a retired J&J treasurer testified.

A Johnson & Johnson attorney on Monday told a New Jersey bankruptcy court judge that its plan to use a subsidiary to resolve talc claims against it is is the best way for a resolution.

A Johnson & Johnson subsidiary came under attack in court on Monday for attempting to use the bankruptcy process to resolve tens of thousands of claims that its baby powder and other talc-based products caused cancer.

By Dietrich Knauth (Reuters) - A Johnson & Johnson subsidiary came under attack in court on Monday for attempting to use the bankruptcy process to resolve tens of thousands of claims that its baby powder and other talc-based products caused cancer. The subsidiary, LTL Management, is fighting to remain in bankruptcy, arguing that is the best way to reach an "equitable, efficient, and consensual resolution" of more than 38,000 claims alleging that J&J''s talc-based products caused cancers including mesothelioma. J&J maintains that its consumer talc products are safe. J&J used a legal maneuver known as the "Texas two-step," which allows companies to split valuable assets from liabilities through a so-called divisive merger. Lawyers representing cancer patients say that the bankruptcy case is meant to delay and frustrate lawsuits that would otherwise go to a jury trial against J&J directly. "At its core, this case is rotten," Jeffrey Jonas, a lawyer for one of the plaintiffs'' committees said during Monday''s opening arguments.

A high-stakes trial kicked off Monday over Johnson & Johnson’s strategy for moving costly talc litigation to bankruptcy court.

If there''s one thing recent macroeconomic and stock market turbulence should reteach us, it''s that the best blue-chip dividend stocks never go out of style. And the Dow''s best dividend stocks are proving that handily so far in 2022. True, inflation is advancing at the fastest pace in four decades, and the market is seething with anxiety over impending interest rate hikes. Yet the top-rated dividend payers among the 30 Dow Jones stocks are beating the market so far this year and should continue to give income investors some much-needed peace of mind. SEE MORE The Pros Picks: 22 Top Stocks to Invest In for 2022 Many of the Dow''s best dividend stocks also happen to be dividend growth stalwarts. Quite a few names in this elite bastion of 30 blue-chip equities are members of the S&P 500 Dividend Aristocrats an index of 66 best dividend stocks that have increased their payouts for at least 25 consecutive years. It''s also noteworthy that the Dow Jones'' best dividend stocks hail from sectors that hold up well when inflation runs hot .